Patents Assigned to Intercept Pharmaceuticals
  • Compositions of obeticholic acid and methods of use
    Patent number: 10646499
    Abstract: The disclosure relates to obeticholic acid formulations with improved stability, dissolution, and/or solubility, methods of preparing the same for use and methods of treating various diseases and conditions.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: May 12, 2020
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Richard Gail Lancaster, Kay K. Olmstead, Masashi Kagihiro, Mitsuhiro Matono, Ikuko Taoka, Mark Pruzanski, David Shapiro, Roya Hooshmand-Rad, Richard Pencek, Cathi Sciacca, Lise Eliot, Jeffrey Edwards, Leigh A. MacConell, Tonya K. Marmon
  • Methods for the preparation of obeticholic acid and derivatives thereof
    Patent number: 10604545
    Abstract: The present application relates to a method of preparing a bile acid derivative or a pharmaceutical acceptable salt, solvate, or amino acid conjugate thereof, comprising direct alkylation of a carbon atom at the C-6 position of 7 keto lithocholic acid (KLCA) with an alkylating agent and reduction of a keto group at the C-7 position.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: March 31, 2020
    Assignee: INTERCEPT PHARMACEUTICALS, INC.
    Inventor: Gabriel M Galvin
  • Methods for preparation of bile acids and derivatives thereof
    Patent number: 10604544
    Abstract: The present application relates to a method of preparing compounds of Formula (A) or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: March 31, 2020
    Assignee: INTERCEPT PHARMACEUTICALS, INC.
    Inventor: Gabriel M Galvin
  • Methods of promoting hepatic regeneration
    Patent number: 10548906
    Abstract: The present invention relates to methods of accelerating, promoting or increasing hepatic regeneration, or increasing liver mass in a subject, by using a compound of formula (A): or a pharmaceutically acceptable salt thereof, and wherein R1, R2, R3, R4, R5, R6, m, and n are as described herein.
    Type: Grant
    Filed: September 21, 2016
    Date of Patent: February 4, 2020
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Peter Leonardus Maria Jansen, Stephanus Willibrordus Maria Olde Damink, Franciscus Gerardus Schaap, Isabelle Anne Leclercq
  • Methods for the preparation of obeticholic acid and derivatives thereof
    Patent number: 10550146
    Abstract: The present application relates to a safe method of preparing a bile acid derivative or a pharmaceutical acceptable salt, solvate, or amino acid conjugate thereof, on a large scale from 7-keto lithocholic acid (KLCA), comprising reacting Compound 2 with paraldehyde to form Compound 3 at a temperature between 10° C. and 30° C.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: February 4, 2020
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Benjamin List, Chandra Kanta De, Qinggang Wang
  • Farnesoid X receptor modulators
    Patent number: 10532061
    Abstract: The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof, wherein R1, R2, R3, R4, R5, and R6 are as described herein. The present invention relates generally to selective FXR agonists and to methods of making and using them.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: January 14, 2020
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventor: Roberto Pellicciari
  • Steroids as agonists for FXR
    Patent number: 10421772
    Abstract: The invention relates to compounds of formula (I): wherein R is ethyl, propyl or allyl, and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof. The compounds of formula (I) are useful as FXR agonists.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: September 24, 2019
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventor: Roberto Pellicciari
  • Methods for preparation of bile acids and derivatives thereof
    Patent number: 10414791
    Abstract: The present application relates to a method of preparing compounds of Formula (I) or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof, R1 is H, ?-OH, ?-OH, or an oxo group.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: September 17, 2019
    Assignee: Intercept Pharmaceuticals, Inc
    Inventors: Roberto Pellicciari, Antimo Gioiello
  • Methods of treating cancer
    Patent number: 10369160
    Abstract: The present invention relates to methods of treating or preventing cancer in a subject in need thereof comprising administering a therapeutically effective amount of a compound of the invention.
    Type: Grant
    Filed: April 11, 2017
    Date of Patent: August 6, 2019
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Antonio Moschetta, Jesus Maria Banales Asurmedi, Luis Bujanda Fernández de Pierola, María Jesús Perugorria Montiel, Oihane Erice Azparren
  • Treatment of fibrosis using FXR ligands
    Patent number: 10258633
    Abstract: The present invention relates to a method for inhibiting fibrosis that occurs in an organ where the farnesoid X receptor (FXR) is expressed. This method involves the step of administering a high potency, activating ligand of FXR in an effective amount to a patient who is not suffering from a cholestatic condition. The invention also provides pharmaceutical compositions containing an effective amount of an FXR ligand and kits for dispensing the pharmaceutical compositions.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: April 16, 2019
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Stefano Fiorucci, Roberto Pellicciari, Mark Pruzanski
  • Process for preparing bile acid derivatives
    Patent number: 10202414
    Abstract: The present invention relates to processes for preparing compounds of formula I or a pharmaceutically acceptable salt or solvate thereof, wherein the dashed bond (----) at position 7 indicates that the substituent is in an ? or ? stereochemistry; R is hydrogen or hydroxy; and R1 is hydrogen or C1-C6 alkyl
    Type: Grant
    Filed: August 21, 2017
    Date of Patent: February 12, 2019
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Roberto Pellicciari, Antimo Gioello
  • Preparation and uses of obeticholic acid
    Patent number: 10174073
    Abstract: The present invention relates to obeticholic acid: or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a FXR mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing HDL cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis. The present invention also relates to processes for the synthesis of obeticholic acid.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: January 8, 2019
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: André Steiner, Heidi Waenerlund Poulsen, Emilie Jolibois, Melissa Rewolinski, Ralf Gross, Emma Sharp, Fiona Dubas-Fisher, Alex Eberlin
  • Preparation and uses of obeticholic acid
    Patent number: 10155787
    Abstract: The present invention relates to obeticholic acid: or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a FXR mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing HDL cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis. The present invention also relates to processes for the synthesis of obeticholic acid.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: December 18, 2018
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: André Steiner, Heidi Waenerlund Poulsen, Emilie Jolibois, Melissa Rewolinski, Ralf Gross, Emma Sharp, Fiona Dubas-Fisher, Alex Eberlin
  • Compositions of obeticholic acid and methods of use
    Patent number: 10052337
    Abstract: The disclosure relates to obeticholic acid formulations with improved stability, dissolution, and/or solubility, methods of preparing the same for use and methods of treating various diseases and conditions.
    Type: Grant
    Filed: April 26, 2016
    Date of Patent: August 21, 2018
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Richard Gail Lancaster, Kay K. Olmstead, Masashi Kagihiro, Mitsuhiro Matono, Ikuko Taoka, Mark Pruzanski, David Shapiro, Roya Hooshmand-Rad, Richard Pencek, Cathi Sciacca, Lise Eliot, Jeffrey Edwards, Leigh A. MacConell, Tonya K. Marmon
  • Preparation and uses of obeticholic acid
    Patent number: 10047117
    Abstract: The present invention relates to obeticholic acid: or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a FXR mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing HDL cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis. The present invention also relates to processes for the synthesis of obeticholic acid.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: August 14, 2018
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: André Steiner, Heidi Waenerlund Poulsen, Emilie Jolibois, Melissa Rewolinski, Ralf Gross, Emma Sharp, Fiona Dubas-Fisher, Alex Eberlin
  • Preparation and uses of obeticholic acid
    Patent number: 9982008
    Abstract: The present invention relates to obeticholic acid: or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a FXR mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing HDL cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis. The present invention also relates to processes for the synthesis of obeticholic acid.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: May 29, 2018
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: André Steiner, Heidi Waenerlund Poulsen, Emilie Jolibois, Melissa Rewolinski, Ralf Gross, Emma Sharp, Fiona Dubas-Fisher, Alex Eberlin
  • Process for preparing bile acid derivatives
    Patent number: 9777038
    Abstract: The present invention relates to processes for preparing compounds of formula I: or a pharmaceutically acceptable salt or solvate thereof.
    Type: Grant
    Filed: October 25, 2013
    Date of Patent: October 3, 2017
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Roberto Pellicciari, Antimo Gioiello
  • Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions
    Patent number: 9763964
    Abstract: The present invention relates to compounds of formula (I): wherein R is hydrogen or alpha-hydroxy, the hydroxyl group in position 7 is in the alpha or beta position; and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: September 19, 2017
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Roberto Pellicciari, Stefano Fiorucci, Mark Pruzanski
  • Steroids as agonists for FXR
    Patent number: 9732117
    Abstract: The invention relates to compounds of formula (I): wherein R is ethyl, propyl or allyl, and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof. The compounds of formula (I) are useful as FXR agonists.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: August 15, 2017
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventor: Roberto Pellicciari
  • Preparation and uses of obeticholic acid
    Patent number: 9732116
    Abstract: The present invention relates to obeticholic acid: or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a FXR mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing HDL cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis. The present invention also relates to processes for the synthesis of obeticholic acid.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: August 15, 2017
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: André Steiner, Heidi Waenerlund Poulsen, Emilie Jolibois, Melissa Rewolinski, Ralf Gross, Emma Sharp, Fiona Dubas-Fisher, Alex Eberlin